Table 1.
Characteristics of included studies
| Study ID | Arms | Patients | Treatments (cycle) | Endpoints | Study design | Lose | Treatment lines | Jada scale |
|---|---|---|---|---|---|---|---|---|
| Dorte L. Nielsen 2011 | Gemcitabine + Docetaxel | 170 | G 1,000 mg/m2 d1,8 + D 75 mg/m2 d8(21d) | OS.ORR.TTP.toxicity | phase3, random,open-label | 6 | First or second-line | 3 |
| Docetaxel | 167 | D 100 mg/m2 d1(21d) | ||||||
| Kathy S. Albain 2008 | Gemcitabin + Paclitaxel | 266 | G 1,250 mg/m2 d1,8 + P 175 mg/m2 d1(21d) | OS.TTP.ORR.toxicity | phase3, random,unclear | 8 | first-line | 3 |
| Paclitaxel | 263 | P 175 mg/m2 d1(21d) | ||||||
| H. Joensuu 2010 | Docetaxel + Gemcitabin(alternating) | 122 | D l100 mg/m2 d1 + G 1000 mg/m2 d1,8(21d) | TTP.OS.ORR.toxicity | phase3, random,open-label | 3 | first-line | 3 |
| Docetaxel | 115 | D l100 mg/m2 d1(21d) | ||||||
| Christos A. Papadimitriou 2009 | Gemcitabin + Docetaxel | 41 | D 35 mg/m2 + G 600 mg/m2(7d) | ORR.OS.TTP.toxicity | phase2, random, unclear | 13 | second-line | 2 |
| Docetaxel | 34 | D 40 mg/m2(7d) | ||||||
| Adam Brufsky 2011 | Gemcitabin + Paclitaxel + Bevacizumab | 93 | P 90 mg/m2 d1, 8, 15 + B 10 mg/kg d1,15 + G 1500 mg/m2 d1, 15(28d) | ORR.PFS.OS.toxicity | phase2, random, open-label | 28 | first-line | 3 |
| Paclitaxel + Bevacizumab | 94 | P 90 mg/m2 d1, 8, 15 + B 10 mg/kg d1, 15(28d) | ||||||
| Vinorelbine | 127 | V 30 mg/m2 d1,8(21d) | ||||||
| C. Levy 2005 | Gemcitabin + Docetaxel | 153 | D 75 mg/m2 d1 + G 1000 mg/m2 d1, 8(21d) | ORR.PFS.TTP.toxicity | Phase3,random,unclear | Unknown | second-line | 2 |
| Capecitabine + Docetaxel | 152 | D 75 mg/m2 d1 + C 1250 mg/m2 bid d1-14(21d) | ||||||
| Zielinski 2005 | Gemcitabine + epirubicin + and paclitaxel(GET) | 124 | G 1,000 mg/m2 d1, 4 + E 90 mg/m2 d1+ P 175 mg/m2 | TTP.ORR.toxicity | Phase3,random,unclear | Unknown | first-line | 3 |
| d1(21d) | ||||||||
| Fluorouracil + Epirubicin + Cyclophosphamide(FEC) | 135 | F 500 mg/m2 d1 + E 90 mg/m2 d1 + C 500 mg/m2 d1(21d) | ||||||
| Stephen Chan 2009 | Gemcitabin + Docetaxel | 153 | G 1000 mg/m2 d1,8 + D 75 mg/m2 d1(21d) | PFS.ORR.OS.toxicity | Phase3,random,unclear | 8 + 3 | first + second-line | 3 |
| Capecitabine + Docetaxel | 152 | C 1,250 mg/m2 bid d1-14 + D 75 mg/m2 d1(21d) |
G = gemcitabine, D = docetaxel, C = capecitabine, F = flurouracil, C = cyclophospham, E = epirubicin, P = paclitaxel, V = vinorelbine, B = bevacizumab, OS = overall survival, ORR = objective response rates, PFS = progression-free survival, TTP = time to progression.